Published in Haematologica on August 30, 2013
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One (2015) 0.76
In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells. Transl Med UniSa (2016) 0.75
Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. Cardiovasc Res (2017) 0.75
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol (2008) 8.30
Apoptosis: a link between cancer genetics and chemotherapy. Cell (2002) 7.86
How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol (2008) 6.02
Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell (2011) 4.91
RasGRP is essential for mouse thymocyte differentiation and TCR signaling. Nat Immunol (2000) 4.28
BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science (2010) 4.01
Induction of apoptosis by cancer chemotherapy. Exp Cell Res (2000) 3.51
Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis (2003) 3.41
RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerol-binding motifs. Science (1998) 3.20
Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J (2011) 3.06
TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res (2009) 2.96
Targeting protein prenylation for cancer therapy. Nat Rev Cancer (2011) 2.60
Faster cyclic loess: normalizing RNA arrays via linear models. Bioinformatics (2004) 2.31
The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem (1997) 1.98
Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J Cell Biol (2011) 1.73
RasGRP1 and RasGRP3 regulate B cell proliferation by facilitating B cell receptor-Ras signaling. J Immunol (2005) 1.70
Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer (2003) 1.67
Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev (2008) 1.60
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood (2006) 1.59
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood (2011) 1.56
Regulation of RasGRP via a phorbol ester-responsive C1 domain. Mol Cell Biol (1998) 1.55
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem (2007) 1.51
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood (2007) 1.48
BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res (2009) 1.45
Farnesyltransferase inhibitors as anticancer agents: critical crossroads. Curr Opin Drug Discov Devel (2004) 1.43
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem (2005) 1.43
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood (2005) 1.38
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood (1997) 1.15
Reutilization of immunoblots after chemiluminescent detection. Anal Biochem (2001) 1.11
Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation. Oncogene (1995) 1.03
Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Cancer Invest (2007) 0.98
Farnesyltransferase inhibitors: mechanism and applications. Expert Opin Investig Drugs (2001) 0.95
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood (2011) 0.95
RasGRP1 is required for human NK cell function. J Immunol (2009) 0.90
Farnesyltransferase inihibitors in hematologic malignancies. Blood Rev (2007) 0.90
Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res (2003) 0.89
High cell surface death receptor expression determines type I versus type II signaling. J Biol Chem (2011) 0.88
R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther (2004) 0.88
Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood (2011) 0.87
Targeted agents in AML: much more to do. Best Pract Res Clin Haematol (2007) 0.85
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc (2008) 8.94
PARP inhibition: PARP1 and beyond. Nat Rev Cancer (2010) 6.70
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol (2004) 6.61
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet (2002) 5.55
The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther (2011) 4.39
Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology (2015) 4.36
A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science (2009) 4.16
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin (2005) 4.06
Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. Radiology (2014) 3.54
Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest (2005) 3.51
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol (2005) 3.41
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res (2005) 3.11
Small cell lung cancer. Mayo Clin Proc (2008) 2.99
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Incidence of childhood distal forearm fractures over 30 years: a population-based study. JAMA (2003) 2.81
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res (2008) 2.76
Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg (2002) 2.68
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood (2012) 2.65
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res (2007) 2.61
Pathophysiology and treatment of hot flashes. Mayo Clin Proc (2002) 2.56
Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes (2003) 2.53
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A (2011) 2.47
Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem (2003) 2.40
Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer (2009) 2.32
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 2.32
Faster cyclic loess: normalizing RNA arrays via linear models. Bioinformatics (2004) 2.31
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
RNA-seq: technical variability and sampling. BMC Genomics (2011) 2.19
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood (2006) 2.18
Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res (2005) 2.15
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
3' tag digital gene expression profiling of human brain and universal reference RNA using Illumina Genome Analyzer. BMC Genomics (2009) 2.12
Novel agents on the horizon for cancer therapy. CA Cancer J Clin (2009) 2.11
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res (2008) 2.03
Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol (2008) 2.01
Advances in chemotherapy of non-small cell lung cancer. Chest (2006) 2.00
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res (2002) 1.92
Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology (2013) 1.91
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood (2008) 1.90
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology (2008) 1.87
Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res (2012) 1.87
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood (2009) 1.86
Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis (2012) 1.84
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol (2006) 1.84
Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO J (2002) 1.82
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer (2008) 1.80
BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res (2008) 1.80
K-ras as a target for cancer therapy. Biochim Biophys Acta (2005) 1.74
Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J Cell Biol (2011) 1.73
S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem (2001) 1.72
miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS One (2011) 1.72
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res (2009) 1.71
MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol (2012) 1.71
Human aromatase: gene resequencing and functional genomics. Cancer Res (2005) 1.71
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol (2006) 1.70
New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol (2009) 1.68
Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res (2009) 1.68
A statistical model for iTRAQ data analysis. J Proteome Res (2008) 1.67
Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev (2007) 1.67
Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell (2004) 1.65
Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood (2002) 1.65
Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer (2007) 1.65
Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem (2007) 1.63
Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2003) 1.61
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol (2005) 1.61
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood (2006) 1.59
Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT. J Bone Miner Res (2006) 1.58
Fracture risk after the diagnosis of Parkinson's disease: Influence of concomitant dementia. Mov Disord (2006) 1.58
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res (2007) 1.57
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood (2011) 1.56
Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS One (2011) 1.55
Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin (2013) 1.54
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol (2003) 1.54
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res (2006) 1.51